Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 9, 1999, Pages 2116-2120

  Andes, D ^a   Van Ogtrop, M ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PREDICTION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032828929     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.9.2116     Document Type: Article

References (30)

1. Anaissie, E. J., N. C. Karyotakis, R. Hachem, M. C. Dignani, J. H. Rex, and V. Paetznick. 1994. Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J. Infect. Dis. 170:384-389.
2. Andes, D., and W. A. Craig. 1998. In vivo activity of amoxicillin and amoxicillin-clavulanate against penicillin-resistant pneumococci in a murine thigh infection model. Antimicrob. Agents Chemother. 42:2375-2379.
3. Blaser, J., B. B. Stone, M. C. Groner, and S. H. Zinner. 1987. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother. 31:1054-1060.
4. Brammer, K. W., P. R. Farrow, and J. K. Faulkner. 1990. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev. Infect. Dis. 12(Suppl. 3):318-326.
5. Craig, W. A., and S. Gudmundsson. 1996. Postantibiotic effect, p. 296-329. In V. Lorlan (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins Co., Baltimore, Md.
6. Craig, W. A., J. Redington, and S. C. Ebert. 1991. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J. Antimicrob. Chemother. 27(Suppl. C):29-40.
7. Craig, W. A., S. Ebert, and Y. Watanabe. 1993. Differences in time above MIC required for efficacy of beta-lactams in animal infection models, abstr. 86, p. 135. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
8. Craig, W. A., and D. Andes. 1996. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr. Infect. Dis. 15:955-962.
9. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
10. Edwards, J. E., and Conference Participants. 1997. International conference for the development of a consensus on the management and prevention of severe candida infections. Clin. Infect. Dis. 25:43-59.
11. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
12. Georgopapadakou, N. H., and T. J. Walsh. 1996. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob. Agents Chemother. 40:279-291.
13. Ghannoum, M. A., J. H. Rex, and J. N. Galgiani. 1996. Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J. Clin. Microbiol. 34:489-495.
14. Harris, S. C., J. E. Wallace, G. Foulds, and M. G. Rinaldi. 1989. Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection. Antimicrob. Agents Chemother. 35:714-716.
15. Humphrey, M. J., S. Jevons, and M. H. Tarbit. 1985. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob. Agents Chemother. 28:648-653.
16. Klepser, M. E., E. J. Wolfe, R. N. Jones, C. H. Nightengale, and M. A. Pfaller. 1997. Antifungal pharmacodynamic characterization of fluconazole and amphotericin B tested against Candida albicans. Antimicrob. Agents Chemother. 41:1392-1395.
17. Loule, A., G. L. Drusano, P. Banerjee, Q. F. Liu, W. Liu, P. Kaw, M. Shayegani, H. Taber, and M. H. Miller. 1998. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob. Agents Chemother. 42:1105-1109.
18. Moore, R. D., P. S. Lietman, and C. R. Smith. 1987. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 155:93-99.
19. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing for yeast. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
20. Nguyen, M. H., J. E. Peacock, A. J. Morris, D. C. Tanner, M. L. Nguyen, D. R. Snydman, M. M. Wagner, M. G. Rinaldi, and V. L. Yu. 1996. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100:617-623.
21. Pfaller, M. A., J. Rhine-Chalberg, S. W. Redding, J. Smith, G. Farinacci, A. W. Fothergill, and M. G. Rinaldi. 1994. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J. Clin. Microbiol. 32: 59-64.
22. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry for the NCCLS Subcommittee on Antifungal Susceptibility Testing. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Clin. Infect. Dis. 24:235-247.
23. Rex, J. H., J. E. Bennett, A. M. Sugar, P. G. Pappas, C. M. van der Horst, J. E. Edwards, R. G. Washburn, W. M. Scheld, A. W. Karchmer, A. P. Dine, M. J. Levenstein, and C. D. Webb. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl. J. Med. 331:1325-1331.
24. Rogers, T. E., and J. N. Galgiani. 1986. Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob. Agents Chemother. 30:418-422.
25. Sangeorzan, J. A., S. F. Bradley, X. He, et al. 1994. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am. J. Med. 97:339-346.
26. Turnidge, J. D., S. Gudmundsson, B. Vogelman, and W. A. Craig. 1994. The postantibiotic effect of antifungal agents against common pathogenic yeast. J Antimicrob. Chemother. 34:83-92.
27. Van't Wont, J., H. Mattle, and R. van Furth. 1989. Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against systemic Candida albicans infection in normal and neutropenic mice. Antimicrob. Agents Chemother. 33:147-151.
28. Vogelman, B., S. Gudmundsson, J. Turnidge, J. Leggett, and W. A. Craig. 1988. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J. Infect. Dis. 157:287-298.
29. Vogelman, B., S. Gudmundsson, J. Leggett, J. Turnidge, S. Ebert, and W. A. Craig. 1988. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158:831-847.
30. Walsh, T. J., J. W. Lee, E. Roilides, P. Francis, J. Bacher, C. A. Lyman, and P. A. Pizzo. 1992. Experimental antifungal chemotherapy in granulocytopenic animal models of disseminated candidiasis: approaches to understanding investigational antifungal compounds for patients with neoplastic diseases. J. Infect Dis. 14(Suppl. 1):139-147.